MissionDMD: FibroGen’s Anti-Fibrosis Program (May 2016)

On May 18, 2016, PPMD and FibroGen hosted a webinar to discuss FibroGen’s investigational drug FG-3019 (which is an anti-CTGF monoclonal antibody) and the launch of FibroGen’s MissionDMD program that is currently being conducted to investigate FG-3019 in Duchenne muscular dystrophy. Specifically, this presentation provided the rationale for evaluating FG-3019 in Duchenne patients and a description of the ongoing clinical trial in non-ambulatory boys with Duchenne. For additional information regarding this study and participating sites please contact Gustavo Lorente (FibroGen Clinical Program Manager): glorente@fibrogen.com or visit http://clinicaltrials.gov (NCT02606136).